[{"orgOrder":0,"company":"LipoMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"DPD","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Oncology \/ Processa Pharmaceuticals"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-PHARM","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ R-PHARM"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 signal","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Epizyme"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Zymeworks","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Zymeworks","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Zymeworks"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB011","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rad51-IN-2","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CG200745","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CrystalGenomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":null,"graph2":null,"graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":null,"graph2":null,"graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Astellas Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Capecitabine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Capecitabine

                          Therapeutic Area : Oncology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Dr. Reddy’s Capecitabine Tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 17, 2021

                          Lead Product(s) : Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Dr Reddy Company Banner

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.

                          Brand Name : Vyloy

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 21, 2024

                          Lead Product(s) : Zolbetuximab,Oxaliplatin,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.

                          Brand Name : Vyloy

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 10, 2024

                          Lead Product(s) : Zolbetuximab,Oxaliplatin,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.

                          Brand Name : PCS6422

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 02, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Cadonilimab, a novel bispecific antibody targets PD-1 and CTLA-4 has been approved in combination with chemotherapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma.

                          Brand Name : AK104

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Cadonilimab,Fluoropyrimidine,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.

                          Brand Name : Vyloy

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 20, 2024

                          Lead Product(s) : Zolbetuximab,Oxaliplatin,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.

                          Brand Name : PCS6422

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 30, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.

                          Brand Name : Vyloy

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 26, 2024

                          Lead Product(s) : Zolbetuximab,Oxaliplatin,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : UTD1 (utidelone) is an investigational tubulin inhibitor, given intravenously in combination with capecitabine for its potential efficacy in patients with HER2-negative breast cancer brain metastases.

                          Brand Name : UTD1

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 05, 2024

                          Lead Product(s) : Utidelone,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.

                          Brand Name : PCS6422

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 11, 2024

                          Lead Product(s) : Eniluracil,Capecitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank